ACR Boston 2014 | Daily Highlights

Effects of 2 Years of Treatment with Romosozumab Followed By 1 Year of Denosumab or Placebo in Postmenopausal Women with Low Bone Mineral Density

Abstract: 916
Presenter: MR McClung
Co-Authors: A Chines, JP Brown, A Diez-Perez, H Resch, J Caminis, MA Bolognese, S Goemaere, HG Bone, JR Zanchetta, J Maddox, O Rosen, S Bray and A Grauer

Background:
We previously reported that 1 year of treatment with the sclerostin antibody romosozumab (Romo) was associated with increased bone mineral density (BMD) and bone formation and with decreased bone resorption in postmenopausal women with low BMD (McClung MR et al., N Engl J Med 2014;370:412-20). Here, we report the results of 2 years of treatment with Romo, followed by 1 year of denosumab (DMAb) or placebo.

Methods:
This phase 2 study enrolled 419 postmenopausal women age 55 to 85 years with a lumbar spine, total hip, or femoral neck T-score ≤–2.0 and ≥–3.5. For the results described here, women received 1 of 5 regimens of Romo (70 mg QM, 140 mg QM, 210 mg QM, 140 mg Q3M, 210 mg Q3M; data for the 210 mg QM group are shown in the figure) or placebo for 2 years. At the end of 2 years, eligible subjects entered a 1-year extension phase and were re-randomized 1:1 within their original treatment group to placebo or DMAb 60 mg Q6M. Only women who entered the extension were included in these analyses.

Results:
Romo led to rapid and marked increases in lumbar spine and total hip BMD during year 1 and continued increases through year 2. The largest gains were observed with Romo 210 mg QM, with BMD increases of 15.7% (lumbar spine) and 6.0% (total hip) (Figure). Women receiving Romo 210 mg QM who transitioned to DMAb continued to accrue BMD at a rate similar to that in the second year of Romo; in those who transitioned to placebo, BMD returned toward pretreatment levels.

Romo induced rapid stimulation of bone formation (P1NP) and decreased bone resorption (CTX). Increases in P1NP were transitory, returning toward baseline within 6 to 12 months and remaining below baseline through year 2. CTX remained below baseline through year 2. In subjects receiving Romo 210 mg QM who transitioned to DMAb, P1NP and CTX decreased; for those who transitioned to placebo, P1NP gradually returned to pretreatment levels, while CTX initially increased above baseline and gradually returned toward baseline.

Adverse events were balanced between the placebo and Romo groups during the first 2 years of the study (with the exception of injection site reactions, most reported as mild) and in the placebo and DMAb groups during year 3.

Conclusions:
Romo led to rapid and marked increases in lumbar spine and total hip BMD over 2 years, which continued with DMAb and resolved after transition to placebo. These data suggest that the treatment effects observed with Romo are further augmented by follow-on treatments like DMAb.

Disclosure of Interest:
M. McClung, Amgen Inc., Merck, 2, Amgen Inc., Lilly, Merck, 5; A. Chines, Amgen Inc., 1, Amgen Inc., 3; J. Brown, Actavis, Amgen Inc., Eli Lilly, Merck, Novartis, 2, Amgen Inc., Eli Lilly, 5, Amgen Inc., Eli Lilly, 8; A. Diez-Perez, Active Life Scientific, 1, Amgen Inc., 2, Lilly, Amgen Inc., 5, Lilly, Amgen Inc., GSK, Novartis, ViiV, 8; H. Resch, None; J. Caminis, UCB Inc., 1, UCB Inc., 3; M. Bolognese, Amgen Inc., Regeneron, Lilly, 2, Amgen Inc., 8; S. Goemaere, Amgen Inc., MSD, Novartis, 2, Amgen Inc., UCB, Eli Lilly, MSD, Novartis, 5, Amgen Inc., Eli Lilly, MSD, Novartis, Servier, Rottapharma, Willpharma, Takeda, 8; H. Bone, Amgen Inc., Merck, Novartis, NPS, 2, Amgen Inc., Merck, Novartis, Tarsa, Noven, 5; J. Zanchetta, Amgen Inc., Eli Lilly, MSD, GSK, 5, Amgen Inc., MSD, Radius Inc., 2; J. Maddox, Amgen Inc., 1, Amgen Inc., 3; O. Rosen, Amgen Inc., 1, Amgen Inc., 3; S. Bray, Amgen Inc., 1, Amgen Inc., 3; A. Grauer, Amgen Inc., 1, Amgen Inc., 3.

Comment:
Mit den in Entwicklung befindlichen Anti-Sklerostin-Inhibitoren Romosozumab, resp. Blosozumab (Abstract 1151, ASBMR, September 2014, Houston: 52-weeks Follow-up of a Phase 2 Study of postmenopausal women with low bone mineral density) stehen zwei hochpotente osteoanabole Substanzen relativ nahe vor Markteinführung. Beide Substanzen zeigen in Phase 2 Studien eine Verbesserung der Knochendichte innert kurzer Zeit, welche diejenige von bisher bekannten Substanzen mehrheitlich übertrifft. Noch bleibt jedoch zu beweisen, dass sich dieser Gewinn an Knochendichte auch in der Reduktion von Frakturen niederschlägt. Eine grosse Phase-3-Studie mit Romosozumab, deren primärer Endpunkt die Reduktion von Wirbelfrakturen ist, wird Anfang 2017 beendet sein. Interessant ist, dass nach Sistieren der Behandlung die Knochendichte sehr schnell wieder auf den Ausgangswert zurückkehrt, weshalb - wie bei der Behandlung mit Teriparatide – eine Anschlusstherapie mit einem Antiresorptivum notwendig sein wird. Die einmal monatliche subkutane Verabreichungsform ist dabei deutlich patientenfreundlicher als das einmal tägliche Injektionsregime der bisher einzigen osteoanabolen Substanz Teriparatide.

Fazit:
Mit Blosozumab und Romosozumab sind vielversprechende Substanzen in Entwicklung, welche die Palette der Osteoporosetherapien im Bereich osteoanaboler Therapieformen erweitern werden.

---

> zurück zur Übersicht